Currently out of the existing stock ratings of Keay Nakae, 180 are a BUY (86.96%), 20 are a HOLD (9.66%), 7 are a SELL (3.38%).

Keay Nakae

Work Performance Price Targets & Ratings Chart

Analyst Keay Nakae, currently employed at CHARDAN CAPITAL, carries an average stock price target met ratio of 42.77% that have a potential upside of 33.35% achieved within 91 days.

Keay Nakae’s has documented 358 price targets and ratings displayed on 32 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on SABS, SAB Biotherapeutics at 15-May-2025.

Wall Street Analyst Keay Nakae

Analyst best performing recommendations are on OCGN (OCUGEN).
The best stock recommendation documented was for OCGN (OCUGEN) at 2/8/2021. The price target of $13 was fulfilled within 1 day with a profit of $2.81 (17.77%) receiving and performance score of 177.74.

Average potential price target upside

of $53.2 (28.51%) on EVLO (EVELO BIOSCIENCES).
of $47.49 (27.7%) on ALNY (ALNYLAM PHARMACEUTICALS).
of $25.13 (72.62%) on AXLA (AXCELLA HEALTH).

ABUS Arbutus Biopharma Corp ARWR Arrowhead Pharmaceuticals AXLA Axcella Health DRNA Dicerna Pharmaceuticals EBS Emergent Biosolutions KLDO Kaleido Biosciences MESO Mesoblast Ltd OCGN Ocugen PEAR Pear Therapeutics SONN Sonnet Biotherapeutics Holdings EVLO Evelo Biosciences FBRX Forte Biosciences LJPC La Jolla Pharmaceutical Co PHGE Biomx PRQR ProQR Therapeutics BV CFRX ContraFect Corp FEMY Femasys NBSE NeuBase Therapeutics RNA Avidity Biosciences SABS SAB Biotherapeutics MCRB Seres Therapeutics SYBX Synlogic ALNY Alnylam Pharmaceuticals BTTX Better Therapeutics DYN Dyne Therapeutics GANX Gain Therapeutics KMDA Kamada OCX OncoCyte Corp SLN Silence Therapeutics PLC XCUR Exicure OMGA Omega Therapeutics IBIO Ibio

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Keay Nakae (CHARDAN CAPITAL)